

TEVA PHARMACEUTICAL INDUSTRIES LTD

Form S-8

September 07, 2017

As filed with the Securities and Exchange Commission on September 7, 2017

No. 333-

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM S-8**  
**REGISTRATION STATEMENT**  
***UNDER***  
***THE SECURITIES ACT OF 1933***

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED**

**(Exact name of registrant as specified in its charter)**

<b>Israel</b>	<b>5 Basel Street</b>	<b>Not Applicable</b>
<b>(State or other jurisdiction of</b>	<b>P.O. Box 3190</b>	<b>(I.R.S. Employer</b>
<b>incorporation or organization)</b>	<b>Petach Tikva, 4951033 Israel</b>	<b>Identification No.)</b>

**(Address of Principal Executive  
Offices)**

**Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan**

**Teva Pharmaceutical Industries Limited 2008 Employee Stock Purchase Plan for U.S. Employees**

**(Full title of the plan)**

**Teva Pharmaceuticals USA, Inc.**

**1090 Horsham Road**

**North Wales, Pennsylvania 19454**

**Attention: Deborah Griffin**

**(215) 591-3000**

**(Name, address and telephone number, including area code, of agent for service)**

*Copy to:*

**Joshua N. Korff, P.C.**

**Ross M. Leff**

**Kirkland & Ellis LLP**

**601 Lexington Avenue**

**New York, New York 10022**

**(212) 446-4800**

Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form S-8

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
 Non-accelerated filer  (Do not check if a smaller reporting company)  Smaller reporting company   
 Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

**CALCULATION OF REGISTRATION FEE**

<b>Title of Each Class of Securities to be Registered (1)</b>	<b>Amount to be Registered (2)</b>	<b>Proposed Maximum Offering Price Per Unit (3)</b>	<b>Proposed Maximum Aggregate Offering Price</b>	<b>Amount of Registration Fee</b>
Ordinary Shares, NIS 0.1 par value, deposited as American Depositary Shares	70,000,000	\$15.40	\$1,078,000,000.00	\$124,940.20

- (1) American Depositary Shares ( ADSs ) issuable on deposit of ordinary shares of Teva Pharmaceutical Industries Limited (the Registrant ), NIS 0.1 par value ( ordinary shares ), have been registered under a separate registration statement. One ADS equals one ordinary share.
- (2) This Registration Statement on Form S-8 (this Registration Statement ) covers 70,000,000 ordinary shares, including (i) 65,000,000 ordinary shares which were approved by the Registrant s shareholders at its Annual Meeting on July 13, 2017 and may be issued under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan (the Incentive Plan ) and (ii) 5,000,000 ordinary shares being registered under the Teva Pharmaceutical Industries Limited 2008 Employee Stock Purchase Plan for U.S. Employees (as amended and restated on September 7, 2017, the ESPP ). The ordinary shares being registered under the Incentive Plan and the ESPP are represented by a like number of ADSs. In addition, this Registration Statement covers an indeterminable number of additional ordinary shares as may hereafter be offered or issued from time to time pursuant to the Incentive Plan or the ESPP to prevent dilution resulting from stock splits, stock dividends or similar transactions effected without the receipt of consideration and pursuant to Rule 416 under the Securities Act of 1933, as amended (the Securities Act ).
- (3) Estimated solely for calculating the amount of the registration fee, pursuant to Rules 457(c) and 457(h) under the Securities Act, based upon the average of the high and low prices per share of the ordinary shares represented by ADSs on September 6, 2017, as reported by The New York Stock Exchange.



## EXPLANATORY NOTE

On September 16, 2008, Teva Pharmaceutical Industries Limited (the Registrant ) filed a Registration Statement on Form S-8 (File No. 333-153503) (the 2008 Registration Statement ) to register 3,500,000 ordinary shares of the Registrant, NIS 0.1 par value ( ordinary shares ), under the Teva Pharmaceutical Industries Limited 2008 Employee Stock Purchase Plan for U.S. Employees (as amended and restated on September 7, 2017, the ESPP ).

On September 3, 2015, the Registrant filed a Registration Statement on Form S-8 (File No. 333-206753) (the 2015 Registration Statement ) to register 46,200,000 ordinary shares, which may be issued under the Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan (the Incentive Plan ).

On August 3, 2016, the Registrant filed a Registration Statement on Form S-8 (File No. 333-212851) (the 2016 Registration Statement ) to register 35,300,000 additional ordinary shares which may be issued under the Incentive Plan.

On October 12, 2016, the Registrant filed a Registration Statement on Form S-8 (File No. 333-214077) (together with the 2008 Registration Statement, the 2015 Registration Statement and the 2016 Registration Statement, the Prior Registration Statements ) to register 300,000 additional ordinary shares subject to the substitute awards that will be issued under the Incentive Plan.

Pursuant to General Instruction E of Form S-8, this Registration Statement on Form S-8 (this Registration Statement ) is filed by the Registrant to register 70,000,000 ordinary shares, including (i) 65,000,000 ordinary shares which were approved by the Registrant's shareholders at its Annual Meeting on July 13, 2017 and may be issued under the Incentive Plan and (ii) 5,000,000 ordinary shares being registered under the ESPP. In accordance with General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference, including all exhibits filed therewith or incorporated therein by reference, except as supplemented, amended or superseded by the information set forth below.

## PART II

### INFORMATION REQUIRED IN THE

### REGISTRATION STATEMENT

#### Item 8. EXHIBITS

The exhibits to this Registration Statement are listed in the Exhibit Index and incorporated herein by reference.

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Petach Tikva, State of Israel, on the 7th day of September, 2017.

TEVA PHARMACEUTICAL INDUSTRIES  
LIMITED

By: /s/ Dr. Yitzhak Peterburg  
Dr. Yitzhak Peterburg

Interim President and Chief Executive  
Officer

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned directors and/or officers of the Registrant hereby constitutes and appoints Yitzhak Peterburg, Michael McClellan, David Stark and Deborah Griffin, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign, execute and deliver with the Commission under the Securities Act any and all post-effective amendments to this Registration Statement and generally to do all things and perform any and all acts and things whatsoever requisite and necessary or desirable to enable the Registrant to comply with the provisions of the Securities Act and all requirements of the Commission.

*[Signatures appear on the following page.]*

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

<b>Name</b>	<b>Title</b>	<b>Date</b>
By: /s/ Dr. Sol J. Barer Dr. Sol J. Barer	Chairman of the Board	September 7, 2017
By: /s/ Dr. Yitzhak Peterburg Dr. Yitzhak Peterburg	Interim President and Chief Executive Officer, Director  (Principal Executive Officer)	September 7, 2017
By: /s/ Michael McClellan Michael McClellan	Senior Vice President and Interim Chief Financial Officer  (Principal Financial Officer)	September 7, 2017
By: /s/ Deborah Griffin Deborah Griffin	Senior Vice President and Chief Accounting Officer  (Principal Accounting Officer)	September 7, 2017
By: /s/ Rosemary A. Crane Rosemary A. Crane	Director	September 7, 2017
By: /s/ Amir Elstein Amir Elstein	Director	September 7, 2017
By: /s/ Murray A. Goldberg Murray A. Goldberg	Director	September 7, 2017
By: /s/ Jean-Michel Halfon Jean-Michel Halfon	Director	September 7, 2017
By: /s/ Gerald M. Lieberman Gerald M. Lieberman	Director	September 7, 2017
By: /s/ Galia Maor Galia Maor	Director	September 7, 2017
By: /s/ Roberto A. Mignone Roberto A. Mignone	Director	September 7, 2017
By: /s/ Dr. Perry D. Nisen Dr. Perry D. Nisen	Director	September 7, 2017
By: /s/ Joseph Nitzani	Director	September 7, 2017

Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form S-8

Joseph Nitzani

By: /s/ Nechemia J. Peres                      Director                      September 7, 2017  
Nechemia J. Peres

By: /s/ Gabrielle Sulzberger                  Director                      September 7, 2017  
Gabrielle Sulzberger

By: /s/ Deborah Griffin                      Authorized U.S. Representative                  September 7, 2017  
Deborah Griffin

Exhibit	Description	Incorporated by Reference				Filed
		Form	File No.	Exhibit	Filing Date	Herewith
4.1	<u>Amended and Restated Deposit Agreement, dated November 5, 2012, among Teva Pharmaceutical Industries Limited, JPMorgan Chase Bank, N.A., as depositary, and the owners and holders from time to time of American Depositary Shares issued thereunder, including the form of American Depositary Receipt contained therein</u>	F-6	333-184652	99.(a)	October 30, 2012	
4.2	<u>Amendment to Deposit Agreement, dated February 29, 2016, among Teva Pharmaceutical Industries Limited, JPMorgan Chase Bank, N.A., as depositary, and the owners and holders from time to time of American Depositary Shares issued thereunder, including the form of American Depositary Receipt contained therein</u>	F-6 POS	333-208239	99.(a)(2)	February 29, 2016	
5.1	<u>Opinion of Tulchinsky Stern Marciano Cohen Levitski &amp; Co.</u>					X
5.2	<u>Opinion of Kirkland &amp; Ellis LLP</u>					X
23.1	<u>Consent of Kesselman &amp; Kesselman Independent Registered Public Accounting Firm to the Registrant</u>					X
23.2	<u>Consent of Tulchinsky Stern Marciano Cohen Levitski &amp; Co. (included in Exhibit 5.1)</u>					X
23.3	<u>Consent of Kirkland &amp; Ellis LLP (included in Exhibit 5.2)</u>					X
24.1	<u>Power of Attorney (included on signature page of this Registration Statement)</u>					X
99.1	<u>Teva Pharmaceutical Industries Limited 2015 Long-Term Equity-Based Incentive Plan</u>	6-K	001-16174	Ex. A	June 8, 2017	
99.2	<u>Teva Pharmaceutical Industries Limited 2008 Employee Stock Purchase Plan for U.S. Employees</u>					X